P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845556.79615.3f |
| _version_ | 1797287254193864704 |
|---|---|
| author | P. Ghia A. Pluta M. Wach D. Lysak M. Simkovic I. Kriachok A. Illes J. de la Serna S. Dolan P. Campbell G. Musuraca A. Jacob E. Avery J. H. Lee G. Usenko M. H. Wang T. Yu W. Jurczak |
| author_facet | P. Ghia A. Pluta M. Wach D. Lysak M. Simkovic I. Kriachok A. Illes J. de la Serna S. Dolan P. Campbell G. Musuraca A. Jacob E. Avery J. H. Lee G. Usenko M. H. Wang T. Yu W. Jurczak |
| author_sort | P. Ghia |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:30:14Z |
| format | Article |
| id | doaj.art-ba0652f510194ac281468814258ad08d |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:30:14Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-ba0652f510194ac281468814258ad08d2024-03-02T06:40:44ZengWileyHemaSphere2572-92412022-06-01656656710.1097/01.HS9.0000845556.79615.3f202206003-00566P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UPP. Ghia0A. Pluta1M. Wach2D. Lysak3M. Simkovic4I. Kriachok5A. Illes6J. de la Serna7S. Dolan8P. Campbell9G. Musuraca10A. Jacob11E. Avery12J. H. Lee13G. Usenko14M. H. Wang15T. Yu16W. Jurczak171 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy2 Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow3 Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland4 Fakultní Nemocnice Plzen, Pilsen5 University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czechia6 National Cancer Institute, Kiev, Ukraine7 University of Debrecen, Faculty of Medicine, Department of Hematology, Debrecen, Hungary8 Hospital Universitario 12 de Octubre, Madrid, Spain9 Saint John Regional Hospital, University of New Brunswick, New Brunswick, Canada10 Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia11 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy12 The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom13 Nebraska Hematology Oncology, Lincoln, Nebraska, United States of America14 Gachon University Gil Medical Center, Incheon, South Korea15 City Clinical Hospital No. 4 DCC, Dnipro, Ukraine16 AstraZeneca, South San Francisco, California17 AstraZeneca, South San Francisco, California, United States of America18 Maria Sklodowska-Curie National Institute of Oncology, Krakow, Polandhttp://journals.lww.com/10.1097/01.HS9.0000845556.79615.3f |
| spellingShingle | P. Ghia A. Pluta M. Wach D. Lysak M. Simkovic I. Kriachok A. Illes J. de la Serna S. Dolan P. Campbell G. Musuraca A. Jacob E. Avery J. H. Lee G. Usenko M. H. Wang T. Yu W. Jurczak P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP HemaSphere |
| title | P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP |
| title_full | P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP |
| title_fullStr | P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP |
| title_full_unstemmed | P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP |
| title_short | P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP |
| title_sort | p668 acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed refractory chronic lymphocytic leukemia ascend results at 4 years of follow up |
| url | http://journals.lww.com/10.1097/01.HS9.0000845556.79615.3f |
| work_keys_str_mv | AT pghia p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT apluta p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT mwach p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT dlysak p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT msimkovic p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT ikriachok p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT ailles p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT jdelaserna p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT sdolan p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT pcampbell p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT gmusuraca p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT ajacob p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT eavery p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT jhlee p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT gusenko p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT mhwang p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT tyu p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup AT wjurczak p668acalabrutinibvsrituximabplusidelalisiborbendamustineinrelapsedrefractorychroniclymphocyticleukemiaascendresultsat4yearsoffollowup |